Skip to content

Advancements in Migraine Therapeutics

The evidence-based recommendation of triptans to treat migraine offers relief for some patients but is not optimal for others and can lead to adverse outcomes in some patients. The introduction of calcitonin gene-related peptide receptor antagonists and monoclonal antibodies has provided a new avenue for acute and chronic migraine management, providing an alternative for patients experiencing medication overuse, triptan intolerance, or contraindications.

Learning Objectives

Upon completion of this activity, the participant will be able to:

  • Describe the underlying pathology of a migraine and the role of neuropeptides in the pathological process
  • Describe step-care and stratified-care models in the management of a migraine patient
  • Explain the role of CGRP receptor antagonists and monoclonal antibodies in the treatment of migraine
  • Discuss the benefits of triptans for acute migraine management

Presenter

Steven J. Crosby, M.A., B.S.P., R.Ph
Steven J. Crosby, M.A., B.S.P., R.Ph., FASCP is a member of the School of Pharmacy-Boston Executive Council, serving as the Assistant Dean of Student Engagement and Success. Steven maintains faculty appointments as an Associate Professor of Pharmacy Practice for MCPHS, and as a Lecturer in Psychiatry for the Boston University School of Medicine. He holds degrees in pharmacy, from MCPHS, and in medical science, from the BU School of Medicine. As a pharmacist, he has practiced in community, rehabilitation hospital, and academic research settings. He maintains research expertise in the areas of behavioral pharmacology, experimental therapeutics, neuroscience, and the scholarship of teaching, publishing in the areas of neuroscience, clinical medicine, pharmacy education and practice, and serving as an author on more than 30 national presentations. His research has been cited in more than 20 peer-reviewed journals, including Frontiers in Psychiatry, the British Journal of Pharmacology, Neuropsychopharmacology, the American Journal of Drug and Alcohol Abuse, and Clinical Neuropharmacology. He serves as an Associate Editor for Clinical Case Reports, with Editorial Board appointments for The Consultant Pharmacist and the American Journal of Health-System Pharmacy. Research experience has led to peer reviewer appointments for more than 15 professional journals. He serves as a consultant to the National Association of Boards of Pharmacy. He is the Chair of the education compliance subcommittee for the American College of Clinical Pharmacology, and has served as the past Chair of the pharmacy practice scholarship and research development committee for the American Association of Colleges of Pharmacy. He is an elected councilor of the American Federation for Medical Research-Eastern Section, and a research grant reviewer for the American Association of Colleges of Pharmacy.

Registration Fee: Free for MCPHS alumni, faculty and staff. For all others the fee is $12.00.

Register

 


 

Release Date: October 21, 2020
Expiration Date: October 21, 2022
Contact Hours: 1.0
Universal Activity Number: ACPE UAN: 0026-0000-20-203-H01-P | Knowledge-based
ACPE Topic Designator: Disease State Management/Drug Therapy

Accreditation

ACPE logo

Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this educational activity for a total of 1.0 contact hours (0.1 CEUs).

Requirements for Credit

In order to receive credit, the participant must view the entire presentation and complete the pre and post-test, and evaluation. Upon completion participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.

Statement of Disclosure

It is the policy of MCPHS-CE to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. All individuals engaged in the planning of a continuing education activity and who are in a position to control the educational content are required to disclose any financial relationships with ineligible companies occurring within the past 24 months. The intent of this policy is to identify and mitigate any potential conflict of interest that may directly or indirectly affect the activity. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

MCPHS will identify, review and mitigate all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Steven J. Crosby has no relevant financial relationships with ineligible companies to disclose.

Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.

No funding from industry provided for this event. No exhibitors will be present.